Evidence map›Paper›PMID 27060768›Full record

ReviewBrain research2017

Studying human disease using human neurons.

Tim Ahfeldt, Nadia K Litterman, Lee L Rubin

Abstract readReview
In one paragraph

Review in Brain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tim AhfeldtDepartment of Stem Cells and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Nadia K LittermanDepartment of Stem Cells and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Lee L RubinDepartment of Stem Cells and Regenerative Biology, Harvard University, Cambridge, MA, USA. Electronic address: lee_rubin@harvard.edu.

Funding

Smn Regulation of Neuromuscular Morphogenesis in DrosophilaP01NS066888 · NINDS · HARVARD MEDICAL SCHOOL · PI ARTAVANIS-TSAKONAS, SPYRIDON · 2010 to 2014
$6.7M
NINDS NIH HHS P01 NS066888
6 · The paper itself

Abstract

Utilizing patient derived cells has enormous promise for discovering new drugs for diseases of the nervous system, a goal that has been historically quite challenging. In this review, we will outline the potential of human stem cell derived neuron models for assessing therapeutics and high-throughput screening and compare to more traditional drug discovery strategies. We summarize recent successes of the approach and discuss special considerations for developing human stem cell based assays. New technologies, such as genome editing, offer improvements to help overcome the challenges that remain. Finally, human neurons derived from patient cells have advantages for translational research beyond drug screening as they can also be used to identify individual efficacy and safety prior to clinical testing and for dissecting disease mechanisms. This article is part of a Special Issue entitled SI: Exploiting human neurons.

Indexed as

Drug DiscoveryAnimalsHumansNervous System DiseasesNeuronsDrug discoveryHuman neurodegenerative diseaseStem cells

Identifiers

PMID27060768
PMCPMC5053850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.